Risk of severe SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in Qatar : a cohort matched study
المؤلفون المشاركون
Alam, Fiaz
al-Sayyid, Umar
Satti, Iman
Becetti, Karimah
Salih, Rawan
Ashur, Hadil
Hamid, Miral
al-Rimawi, Yusuf
Nadir, Joanne
Chaponda, Masautso
Awad, Basim
Hammudah, Muhammad
al-Imadi, Samar
المصدر
العدد
المجلد 2022، العدد 3 (31 ديسمبر/كانون الأول 2022)، ص ص. 1-9، 9ص.
الناشر
تاريخ النشر
2022-12-31
دولة النشر
قطر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background: It remains unclear whether patients with autoimmune rheumatic diseases (ARDs) are at a higher risk of poor outcomes from a SARS-CoV-2 infection.
We evaluated whether patients with an ARDs infected with SARS-CoV-2 were at a higher risk of a poorer outcome than those without an ARDs.
Methods: Patients with an ARDs infected with SARS-CoV-2 were matched to control patients without a known ARDs.
Matching was performed according to age ( ± 6 years) and sex at a case-to-control ratio of 1:3.
Demographic and clinical data were extracted from the databases and were compared between the two groups.
Severe SARS-CoV-2 infection was the primary outcome and was defined as the requirement for oxygen therapy support, the need for invasive or noninvasive mechanical ventilation, or the use of glucocorticoids.
Results: A total of 141 patients with an ARDs were matched to 398 patients who formed the control group.
The mean ages (SD) of the ARDs and non-ARDs groups were 44.4 years (11.4) and 43.4 years (12.2).
Women accounted for 58.8% of the ARDs group and 56.3% of the control group (p = 0.59).
Demographics and comorbidities were balanced between the groups.
ARDs included connective tissue disease in 43 (30.3%) patients, inflammatory arthritis in 92 (65.2%), and other ARDs in 8 (5.7%).
ARDs medications included biological/targeted synthetic disease-modifying antirheumatic drugs (b/ts-DMARDs) in 28 (15.6%) patients, conventional synthetic DMARDs in 95 (67.4%), and immunosuppressive antimetabolites in 13 (9.2%).
The ARDs group had more respiratory and gastrointestinal symptoms related to SARS-CoV-2 infection than the control group (24.8% and 20.6% vs.
10% and 5.3%, respectively; p < 0.001 for both).
Severe SARS-CoV-2 infection was more common in the ARDs group than in the control group (14.9% vs.
5.8%; p < 0.001).
Conclusions: In this single-center matched cohort study, patients with an ARDs experienced more respiratory and gastrointestinal symptoms related to SARS-CoV-2 infection and had more severe infection than those from the control group.
Therefore, patients with an ARDs require close observation during the coronavirus disease 2019 pandemic.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
al-Sayyid, Umar& al-Imadi, Samar& Satti, Iman& Becetti, Karimah& Salih, Rawan& Ashur, Hadil…[et al.]. 2022. Risk of severe SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in Qatar : a cohort matched study. Qatar Medical Journal،Vol. 2022, no. 3, pp.1-9.
https://search.emarefa.net/detail/BIM-1437747
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
al-Sayyid, Umar…[et al.]. Risk of severe SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in Qatar : a cohort matched study. Qatar Medical Journal No. 3 (2022), pp.1-9.
https://search.emarefa.net/detail/BIM-1437747
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
al-Sayyid, Umar& al-Imadi, Samar& Satti, Iman& Becetti, Karimah& Salih, Rawan& Ashur, Hadil…[et al.]. Risk of severe SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in Qatar : a cohort matched study. Qatar Medical Journal. 2022. Vol. 2022, no. 3, pp.1-9.
https://search.emarefa.net/detail/BIM-1437747
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references : p. 8-9
رقم السجل
BIM-1437747
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر